banner
 
bar

program

slides
bar
 
 

Optimizing Cardiovascular Outcomes in Type 2 Diabetes

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

2.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in Type 2 diabetes

Release Date

July 22, 2013

Expiration Date

July 22, 2015

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period July 22, 2013 through July 22, 2015, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 8 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logo

This activity is supported by an independent medical education grant from the Bristol-Myers Squibb and AstraZeneca Pharmaceuticals LP, Alliance Partners.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

VIVIAN FONSECA, MD, FRCP
(Program Co-Chair)
Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA

Research Support (to Tulane): Eli Lilly, Abbott, Reata, Asahi
Honoraria for Consulting and Lectures: Glaxo Smith Kline, Takeda, Novo Nordisk,
sanofi-aventis, Eli Lilly, Pamlabs, Astra-Zeneca, Abbott, Bristol-Myers Squibb, Merck, Boehringer Ingelheim



A. MICHAEL LINCOFF, MD
(Program Co-Chair)
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, C5 Research
Cleveland Clinic
Cleveland, OH

Consultant: Ikaria, Roche, CSL Behring, Janssen
Research Support: Aastrom, Anthera, AstraZeneca, BMS, Centocor,
Edward Lifesciences, Eli Lilly (PI), Ethicon, J&J,
Juventas, Kai Pharmaceuticals (PI), Karo Bio,
Medtronic, Merck/Schering-Plough (Nat’l
Coordinator), Novartis, Pfizer (Co-PI), Regado (Co-
PI), Reserverlogix, Roche (PI), Sanofi-aventis, Scios,
Takeda (PI), VIVUS (PI)

DEREK LEROITH, MD, PhD
Director of Research
Mount Sinai School of Medicine
Professor of Medicine
Mount Sinai Hospital
New York, NY

Consultant: Merck, Janssen, Sanofi-aventis, Novo Nordisk
Grant/Research Support: sanofi-aventis


BENJAMIN M. SCIRICA, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Cardiologist
Brigham and Women’s Hospital
Boston, MA

Nothing to disclose

RALPH DEFRONZO, MD
Professor of Medicine
Chief, Diabetes Division
University of Texas Health Science Center at San Antonio
San Antonio, TX

Advisory Board: Amylin, Takeda, BMA, Novo Nordisk, Janssen,
Boehringer Ingelheim
Speaker’s Bureau: Novo Nordisk
Grant/Research Support: Amylin, Takeda
Speaker’s Bureau: Warner-Chilcott

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Better understand and have improved awareness of the epidemiology, disease burden, scientific knowledge base, and landmark trials that explain the central importance of cardiovascular disease as a dreaded complication of, and comorbid condition associated with, diabetes;
  • Deploy and appropriately sequence pharmacologic interventions that can optimize CV risk reduction in patients with diabetes;
  • Understand the clinical implications of the multiple molecular mechanisms, biomarkers, and cardiometabolic risk factors (hyperlipidemia, hyperglycemia, increased weight, hypertension, postprandial hyperglycemia, and others) that underlie development of cardiovascular disease in diabetic patients;
  • Adhere to to the Year 2012 ADA/EASD guidelines for T2D management, with a focus on the cardiovascular dimensions of diabetes care;
  • Understand the mechanisms of action of agents used to manage T2D and how best to deploy multiple pharmacologic interventions, across the therapeutic continuum for diabetes, including incretin-based therapies (GLP-1 agonist and DPP-4 inhibitors), as well as other glycemia-regulating approaches, that are part of a multimodal, guideline-sanctioned strategy for individualized management of patients with T2D;

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2013 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

A1C
AACE
Acarbose
ACE
Actos
ADA
AGI
Alpha Glucosidase Inhibitor
Apidra
Avandia
Bromocriptine
Byetta
Colesevelam
Detemir
Diabetes
Diabetes Mellitus
DPP-IV inhibitors
EASD
Exenatide
GAD-65
Glargine
Glimepiride
Glipizide
glucagon
glucophage


Glucosidase inhibitors
Glyburide
Humalog
Hyperglycemia
Hypoglycemia
IA2
Incretin
Injectables
Insulin
Islets
Isophane
Januvia
ketoacidosis
Liraglutide
Metformin
Miglitol
Neuropathy
Novolog
Insulin ratio
Onglyza
pancreas
Pramlintide
proinsulin
SGLT2-inhibitors
Sitagliptin
Sulfonylureas
Symlin
Thiazolidinediones

Type 2 Diabetes
Glucose
UKPDS
Victoza
b-Cell
A1c
AACE
AACE/ACE
ACCORD
ADA
ADA/EASD
ADVANCE
Basal Insulin
DCCT
DPP-4 inhibitor
Dyslipidemia
ESRD
Exenatide
FPG
Glargine
glimiperide
GLP agonist
Glucose
glyburide
Glycemia

Glycemic
HbA1c
HDL
Hypertension
Hypoglycemia
incretin
Insulin
Insulin detemir
insulinopenia
LDL
metformin
Microalbumin
NHANES
NPH
Obesity
PPG
prandial
PREMIX
Sulfonylureas
T2D
T2DM
Thiazolidinedione
troglitazone
TZD
UKPDS
VADT